Core Viewpoint - Novo Nordisk's GLP-1 receptor agonist, Ozempic® (semaglutide injection), has received approval from the National Medical Products Administration (NMPA) in China for an updated label that includes benefits for patients with peripheral artery disease (PAD) [4] Group 1: Clinical Trial Results - The update is based on the STRIDE clinical trial results, which demonstrated that Ozempic® 1.0mg significantly improves walking ability in patients with type 2 diabetes and PAD, increasing the maximum walking distance by 13% and showing an average treatment difference of 39.9 meters [4] Group 2: Treatment Options - Type 2 diabetes is a primary risk factor for PAD, with nearly one-third of PAD patients also having type 2 diabetes. Currently, there are limited treatment options specifically aimed at improving walking ability in this population, making the updated label for Ozempic® a new treatment choice for these patients [5] Group 3: Progress of Ozempic® in China - Since its launch, Ozempic® has progressed through various indications in China, receiving dual indications for glycemic control and cardiovascular event reduction in 2021, becoming the first and only GLP-1 RA weekly formulation with cardiovascular indications in the country. It was included in the national medical insurance the same year [6] - By July 2025, it will gain an additional indication for chronic kidney disease, making it the first GLP-1 drug in China with three indications: diabetes, cardiovascular, and kidney [6] - The inclusion of PAD benefits marks an upgrade in its "multiple protections" for Chinese patients [6]

Core Insights - Novo Nordisk has launched a modern warehouse and logistics center at Shanghai Pudong International Airport, enhancing its supply chain capabilities for diabetes and obesity treatments [1][3] Group 1: Warehouse and Logistics Center - The new warehouse and logistics center is a significant upgrade in Novo Nordisk's operations in China, expected to receive drug and medical device operating licenses by the end of 2024 [3] - The facility features temperature-controlled storage systems, including 2℃-8℃ and 15℃-25℃ zones, and is equipped with advanced management and monitoring systems to ensure safety and efficiency [3] - This center is a key component of Novo Nordisk's supply chain in China, reinforcing Shanghai's role as a commercial and innovation hub for the company [3][4] Group 2: Innovation and Collaboration - The warehouse is part of Novo Nordisk's Open Innovation Center in China, which aims to foster collaboration across various fields, including digital health and logistics [4] - The company has introduced 22 innovative drugs and 11 injection devices to China over its 31 years in the market, with Shanghai serving as a pivotal point for its ongoing engagement with the Chinese market [4][5] Group 3: Upcoming Events and Product Developments - At the upcoming China International Import Expo, Novo Nordisk will showcase its latest developments, including the integration of cardiovascular benefits into the product instructions for its weight management drug [5] - The company will also present clinical research findings on innovative combination therapies and long-acting growth hormone treatments at the expo [5]

Core Viewpoint - Novo Nordisk has received approval from the National Medical Products Administration (NMPA) for its drug, Ozempic® (semaglutide injection), to be used for a new indication in chronic kidney disease (CKD) [1] Group 1: Company Developments - Novo Nordisk's Ozempic® is now the first and only GLP-1 receptor agonist (GLP-1RA) approved in China for reducing the risk of sustained decline in eGFR, end-stage kidney disease, and cardiovascular death in adult patients with type 2 diabetes and CKD [1]

Core Insights - Ark Health has launched Novo Nordisk's innovative diabetes medications, including the injectable Semaglutide (Nuohe Tai®) and oral Semaglutide (Nuohe Xin®), aiming to provide effective treatment for a broader range of adult type 2 diabetes patients [1] Group 1: Product Launch and Features - Nuohe Tai® is a GLP-1 receptor agonist that has been well-received since its launch in China in 2021 due to its excellent glycemic control and convenient once-weekly dosing [1] - Nuohe Xin®, the world's first oral GLP-1 receptor agonist, was fully launched in China in January 2025, utilizing "SNAC absorption enhancer" technology to facilitate daily oral administration [1] Group 2: Market Context - China has the highest number of type 2 diabetes patients globally, with approximately 148 million patients aged 20-79, accounting for over a quarter of the world's total [1] - The prevalence of overweight/obesity, dyslipidemia, and hypertension is notably high among these patients, indicating a significant health need [1] Group 3: Future Strategy - The company plans to continue integrating digital intelligence with internet healthcare services, establishing strategic partnerships with leading biopharmaceutical companies to create a new landscape for smart healthcare [2] - The goal is to transform cutting-edge medical research into accessible chronic disease management solutions, enhancing service quality for chronic disease patients [2]